Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
URST1 siRNA
- Development stage
- Preclinical
- Lead developer
- University of Tokyo
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intraperitoneal
01
Overview
URST1 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Up-regulated in solid tumor 1 (URST1), a protein identified as a prognostic marker and therapeutic target in lung cancer. URST1 is frequently overexpressed in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), where it correlates with poor patient prognosis and increased malignancy. By targeting URST1 mRNA for degradation, the siRNA inhibits the growth and invasive capabilities of lung cancer cells. Research conducted by the University of Tokyo and associated institutions suggests that URST1 plays an essential role in oncogenic signaling pathways, and its knockdown leads to G2/M arrest and cell death.
- Other names
- siRNA against URST1URST1-targeting siRNAURST-1-targeting siRNAURST 1-targeting siRNA
02
Targets
URST1 (Up-regulated in solid tumor 1)
Beyond the preview
Go deeper on URST1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on URST1 siRNA.